The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial - Concepedia

Concepedia

Publication | Open Access

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

DOI Full Paper Access

32

Citations

21

References

2023

Year

Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu,

Clinical Cancer Research

Abstract

Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory patients with FL who had received at least two prior systemic therapies.

References

	Year	Citations

Page 1